What is the recommended treatment for squamous cell carcinoma of the nasopharynx?

Treatment of Squamous Cell Carcinoma of the Nasopharynx

For non-metastatic nasopharyngeal carcinoma, radiation therapy using IMRT is the definitive treatment, with concurrent cisplatin-based chemoradiotherapy required for stage III-IVA disease to maximize survival and locoregional control. 1

Treatment by Stage

Early Stage Disease (Stage I-II)

• Stage I and IIA: Radiation therapy alone is the standard treatment 2
• Stage II with IMRT: RT alone is appropriate when intensity-modulated radiation therapy is used 1
• Stage IIB: Often treated with the same strategies as stage III-IV disease due to intermediate risk 2

Radiation dosing: 70 Gy total dose is required for macroscopic tumor eradication, with 50-60 Gy for elective treatment of at-risk sites 2, 1. IMRT or VMAT techniques are mandatory to minimize xerostomia and late toxicity 1.

Locally Advanced Disease (Stage III-IVA)

The standard treatment is concurrent chemoradiotherapy 1. The evidence strongly supports:

Primary regimen: Cisplatin 100 mg/m² every 3 weeks during radiation therapy 1

• Alternative: Weekly cisplatin 40 mg/m²/week has also shown OS improvement 1
• Minimum cumulative cisplatin dose should exceed 200 mg/m² 1

For cisplatin-unfit patients: Concurrent nedaplatin is non-inferior to cisplatin 1, while carboplatin has conflicting evidence 1

Treatment Intensification

Induction chemotherapy followed by concurrent chemoradiotherapy is now a validated standard for stage III-IVA non-keratinizing NPC 1.

Recommended induction regimen: Cisplatin plus gemcitabine for 2-3 cycles (preferably 3 cycles), followed by concurrent chemoradiotherapy 1, 3

• This approach improves recurrence-free survival, overall survival, and distant recurrence-free survival 1
• Start RT within 21-28 days from day 1 of the last induction cycle 3

Alternative induction regimens: TPF (docetaxel, cisplatin, 5-FU) or PF (cisplatin, 5-FU) can be used based on patient status 3

Adjuvant chemotherapy: PF regimen (cisplatin 80 mg/m² day 1 + 5-FU 1000 mg/m²/day continuous infusion days 1-4) every 4 weeks for 3 cycles after concurrent chemoradiotherapy 3. However, completion rates are poor (46-78%), and the role remains debatable 1.

Recurrent/Metastatic Disease

Locoregional Recurrence

Small local recurrences are potentially curable 1:

• Nasopharyngectomy is first-line for recurrent disease stages rT1-rT3 not invading the carotid artery or extending intracranially 1
• Alternatives: brachytherapy, radiosurgery, stereotactic RT, or re-irradiation with IMRT ± chemotherapy 1
• Neck dissection for lymphatic recurrences in the neck 1

Metastatic Disease

First-line: Cisplatin plus gemcitabine combination chemotherapy improves overall survival 1

• Addition of locoregional RT to systemic therapy in newly diagnosed metastatic NPC improves locoregional control and OS 1

Second-line: No standard exists. Active single agents or combinations include paclitaxel, docetaxel, 5-FU, capecitabine, irinotecan, vinorelbine, ifosfamide, doxorubicin, oxaliplatin, and cetuximab 1

• Immunotherapy is promising but positioning remains undefined 1
• Oligometastatic patients may achieve long-term survival with aggressive treatment including chemotherapy, surgery, or definitive RT to metastases 1

Critical Technical Points

Radiation therapy targets: Primary tumor, pathological nodes, adjacent at-risk regions, and generally both sides of the neck (levels II-V and retropharyngeal nodes) 1

Avoid: Fractional doses >2 Gy per fraction and excessive acceleration with multiple fractions >1.6 Gy/fraction to minimize late neurological toxicity 2

Important Caveats

• Nasopharyngeal carcinoma is distinct from other head and neck squamous cell carcinomas and should not be managed with the same protocols as oral cavity, larynx, oropharynx, or hypopharynx cancers 4, 2
• The provided guidelines for oral cavity/larynx/oropharynx/hypopharynx [5-5-5] are not applicable to nasopharyngeal carcinoma
• Surgery has no role in primary treatment of nasopharyngeal carcinoma except for biopsy, managing otitis media with effusion, or treating select recurrences 6
• All treatment decisions should be made in a multidisciplinary tumor board at high-volume facilities 1